CARDIOPHARMA ApS: Financial statements 2024
CVR: 13966273
Source: annual report 2024, Danish Business Authority
01/05/2023 – 30/04/2024
CARDIOPHARMA ApS (CVR 13966273) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK 2,618,264 and a net result of DKK 2,910,302 compared with DKK 1,018,640 the year before. That is an increase of 497.8% compared with the year before. Equity in the 2024 report amounted to DKK 28,260,295. The solvency ratio was 99.8%.
- Revenue
- DKK 0
- Gross Profit
- DKK 2,618,264
- Profit/Loss
- DKK 2,910,302
- Equity
- DKK 28,260,295
- Total Assets
- DKK 28,303,019
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | 0 | 2.6M | 2.9M | 28.3M | 0 |
| 2023 | 0 | 438K | 1M | 28M | 1 |
| 2022 | 0 | 3.4M | 2.9M | 28M | 1 |
| 2021 | 0 | 811K | 4.3M | 30.1M | 1 |
| 2020 | - | 2.4M | 1.6M | 26.2M | 1 |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningAbout CARDIOPHARMA ApS
CARDIOPHARMA ApS is a Danish company of the type Anpartsselskab based in Gentofte, founded in 1990. The company is registered under the industry Virksomhedsrådgivning og anden ledelsesrådgivning. The company was previously named KM 455 ApS. The management consists of Niels Christian Fischer Petersen. The company is owned by Niels Christian Fischer Petersen. According to the 2026 annual report, the company had an average of 0 employees. In 2026, the company reported a gross profit of DKK 4,336,132 and a net result of DKK 3,090,043 compared with DKK 1,968,388 the year before. Equity in the 2026 report amounted to DKK 31,593,726.